Literature DB >> 17899077

Adoptive transfer of T(reg) depleted autologous T cells in advanced renal cell carcinoma.

Fiona C Thistlethwaite1, Eyad Elkord, Richard W Griffiths, Deborah J Burt, Alaaeldin M Shablak, John D M Campbell, David E Gilham, Eric B Austin, Peter L Stern, Robert E Hawkins.   

Abstract

PURPOSE: CD4(+)CD25(+) regulatory T (T(reg)) cells are present in increased numbers in patients with advanced cancer and CD25(+) T cell depletion potentiates tumour immunity in animal models. The aim of this study was to assess the feasibility and safety of adoptive transfer of CD25(+) depleted autologous T cells in patients with advanced renal cell carcinoma and to examine resulting changes in lymphocyte subsets. PATIENTS AND METHODS: Six patients with advanced renal cell carcinoma underwent leukapheresis followed by conditioning chemotherapy with cyclophosphamide and fludarabine. The autologous leukapheresis product was depleted of CD25(+) cells using CliniMACS System then re-infused into the patient.
RESULTS: Efficient CD25(+) depletion from all leukapheresis products was achieved and 0.55-5.87 x 10(7)/kg CD3(+) cells were re-infused. Chemotherapy related haematological toxicity was observed, but blood counts recovered in all patients allowing discharge after a mean inpatient stay of 21 days. One patient subsequently developed a rapidly progressive neurological syndrome. A transient reduction in CD25(+) subset was noted in the peripheral blood of 5 out of 6 patients with evidence of increased T cell responses to PHA in 4 out of 6 patients. One patient showed increased specific proliferative responses to the tumour associated antigen h5T4 coinciding with the nadir of T(reg) cells.
CONCLUSIONS: Given the transient nature of the reduction in CD25(+) subset and the observed toxicity there is a need to explore further strategies to improve the safety and efficacy of this approach. Nevertheless, the results provide proof of concept in potentiation of tumour antigen T cell responses when T(reg) cell levels are depleted.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17899077     DOI: 10.1007/s00262-007-0400-6

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  11 in total

1.  Cyclophosphamide enhances the immunosuppressive action of its own active metabolites.

Authors:  L Y Telegin; V M Pisarev; L A Pevnitsky
Journal:  Dokl Biol Sci       Date:  2008 Nov-Dec

2.  The long road to immunotherapy for childhood rhabdomyosarcoma.

Authors:  Elaine Huang; Brian P Rubin; Charles Keller
Journal:  Pediatr Blood Cancer       Date:  2011-07-08       Impact factor: 3.167

Review 3.  Redirecting the immune response: role of adoptive T cell therapy.

Authors:  Anna Mondino; Valérie Dardalhon; Rodrigo Hess Michelini; Severine Loisel-Meyer; Naomi Taylor
Journal:  Hum Gene Ther       Date:  2010-05       Impact factor: 5.695

4.  Enrichment of CD8+ cells from melanoma tumor-infiltrating lymphocyte cultures reveals tumor reactivity for use in adoptive cell therapy.

Authors:  Peter A Prieto; Katherine H Durflinger; John R Wunderlich; Steven A Rosenberg; Mark E Dudley
Journal:  J Immunother       Date:  2010-06       Impact factor: 4.456

5.  Murine rhabdomyosarcoma is immunogenic and responsive to T-cell-based immunotherapy.

Authors:  Joanna L Meadors; Yonghzi Cui; Qing-Rong Chen; Young K Song; Javed Khan; Glenn Merlino; Maria Tsokos; Rimas J Orentas; Crystal L Mackall
Journal:  Pediatr Blood Cancer       Date:  2011-04-01       Impact factor: 3.167

Review 6.  Harnessing innate and adaptive immunity for adoptive cell therapy of renal cell carcinoma.

Authors:  Christiane Geiger; Elfriede Nössner; Bernhard Frankenberger; Christine S Falk; Heike Pohla; Dolores J Schendel
Journal:  J Mol Med (Berl)       Date:  2009-03-07       Impact factor: 4.599

Review 7.  Cellular immunotherapy for ovarian cancer.

Authors:  Martin J Cannon; Timothy J O'Brien
Journal:  Expert Opin Biol Ther       Date:  2009-06       Impact factor: 4.388

Review 8.  Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effects.

Authors:  Ulf Petrausch; Christian H Poehlein; Shawn M Jensen; Chris Twitty; James A Thompson; Ilka Assmann; Sachin Puri; Michael G LaCelle; Tarsem Moudgil; Levi Maston; Kevin Friedman; Sarah Church; Elisa Cardenas; Daniel P Haley; Edwin B Walker; Emmanuel Akporiaye; Andrew D Weinberg; Sidney Rosenheim; Todd S Crocenzi; Hong-Ming Hu; Brendan D Curti; Walter J Urba; Bernard A Fox
Journal:  Curr Mol Med       Date:  2009-08       Impact factor: 2.222

Review 9.  Suppression, subversion and escape: the role of regulatory T cells in cancer progression.

Authors:  K Oleinika; R J Nibbs; G J Graham; A R Fraser
Journal:  Clin Exp Immunol       Date:  2013-01       Impact factor: 4.330

Review 10.  Adoptive T-cell therapy for cancer in the United kingdom: a review of activity for the British Society of Gene and Cell Therapy annual meeting 2015.

Authors:  David Edward Gilham; John Anderson; John Stephen Bridgeman; Robert Edward Hawkins; Mark Adrian Exley; Hans Stauss; John Maher; Martin Pule; Andrew Kelvin Sewell; Gavin Bendle; Steven Lee; Waseem Qasim; Adrian Thrasher; Emma Morris
Journal:  Hum Gene Ther       Date:  2015-05       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.